Company / Gross Profit
NeoGenomics Laboratories, Inc. Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$314.3M
FY2025
5-year range
$187.1M / $314.3M
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
#70 of 100
Health Care
What the data says
At $314M, NeoGenomics Laboratories, Inc.'s gross profit ranks #70 of 100 in the Health Care sector. Gross Profit has increased for 5 consecutive years, from $186M in FY2020 to $314M in FY2025.
Based on SEC 10-K filings.
$314M in FY2025 with a 5-year CAGR of +11.1%.
Improved from $245M to $314M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +18.7%
- 5-Year CAGR
- +11.1%
- 10-Year CAGR
- -
Sector benchmark
#70 of 100 in Health CareTop 70% of 100This company $314.3M Sector average $1.8B
▼
-82.7% below sector average
Key checks
Key Insights
- NeoGenomics Laboratories, Inc.'s gross profit has grown for 5 consecutive years.
- 5-year CAGR of +11.1%, indicating consistent growth.
- In FY2025, gross profit increased 8.3% year-over-year.
- Ranks #70 out of 100 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $314.3M | +8.3% |
| FY2024 | $290.1M | +18.6% |
| FY2023 | $244.6M | +30.2% |
| FY2022 | $187.9M | +0.4% |
| FY2021 | $187.1M | +0.6% |
| FY2020 | $185.9M | -5.6% |
| FY2019 | $196.8M | +54.7% |
| FY2018 | $127.3M | +24.8% |
| FY2017 | $102.0M | +3.9% |
| FY2016 | $98.1M | +124.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026